Skip to main content
TipRanks
Go Ultimate75% OFF

NovaBridge Biosciences (NBP) Stock Price & Analysis

432 Followers

NBP Stock Chart & Stats

$0.83-$0.05(-5.57%)
At close: 4:00 PM EST
$1$1.5$2Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$0.83 - $0.98
52-Week Range
$0.75 - $5.19
Previous Close
$0.88
Volume
N/A
Average Volume (3M)
557.23K
Market Cap
$102.06M
Enterprise Value
$39.26M
Total Cash (Recent Filing)
$190.85M
Total Debt (Recent Filing)
$4.46M
Price to Earnings (P/E)
―
Beta
1.15
Next Earnings
Mar 31, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Givastomig Clinical And Regulatory Progress

Givastomig has produced mature efficacy data, durable follow-up and a clearer regulatory path toward registrational development. FDA engagement, Fast Track and broad activity across CLDN18.2 expression levels could support differentiation and expand the potential addressable patient population.

Liquidity And Low Financial Leverage

Substantial liquidity and no debt provide flexibility to advance clinical programs through important milestones without immediate balance-sheet leverage pressure. The stated runway supports continued development and gives management time to pursue financing or partnerships on more strategic terms.

Broadening Multi-asset Pipeline

The VIS-102 license broadens NovaBridge’s exposure beyond its lead oncology program and VIS-101, creating another potential ophthalmology franchise in a rare disease. A wider pipeline can diversify clinical catalysts and support future partnering or portfolio value creation.

Bears Say

Persistent Losses And Cash Burn

Recurring operating losses, near-zero recent revenue and multi-year negative cash flow show that NovaBridge has not established a self-sustaining commercial or financial model. Continued investment therefore depends on liquidity, financing or partnerships while clinical assets mature.

Phase 3 Financing Dependency

The timing of pivotal development remains conditional on obtaining additional capital, creating a direct link between financing execution and clinical progress. Delays or unfavorable funding could slow the lead program, increase dilution, or force prioritization across NovaBridge’s pipeline.

Competitive And Clinical Scope Uncertainty

Competition from multiple CLDN18.2 approaches raises the bar for proving meaningful differentiation in efficacy, safety or convenience. Unresolved development plans for PD-L1-negative patients may also limit the eventual label or require additional evidence, increasing execution complexity.

NovaBridge Biosciences News

NBP FAQ

What was NovaBridge Biosciences’s price range in the past 12 months?
NovaBridge Biosciences lowest stock price was $0.75 and its highest was $5.19 in the past 12 months.
What is NovaBridge Biosciences’s market cap?
NovaBridge Biosciences’s market cap is $102.06M.
When is NovaBridge Biosciences’s upcoming earnings report date?
NovaBridge Biosciences’s next earnings report is estimated for Mar 31, 2027 (not yet confirmed), which is in 130 days.
How were NovaBridge Biosciences’s earnings last quarter?
NovaBridge Biosciences released its earnings results on Aug 20, 2026. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.12 by -$0.04.
Is NovaBridge Biosciences overvalued?
According to Wall Street analysts NovaBridge Biosciences’s price is currently Undervalued.
Does NovaBridge Biosciences pay dividends?
NovaBridge Biosciences does not currently pay dividends.
What is NovaBridge Biosciences’s EPS estimate?
NovaBridge Biosciences’s EPS estimate is -0.19.
How many shares outstanding does NovaBridge Biosciences have?
NovaBridge Biosciences has 115,381,690 shares outstanding.
What happened to NovaBridge Biosciences’s price movement after its last earnings report?
NovaBridge Biosciences reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.12. Following the earnings report the stock price went down -3.535%.
Which hedge fund is a major shareholder of NovaBridge Biosciences?
Hedge funds hold NovaBridge Biosciences shares: the largest hedge-fund position in NovaBridge Biosciences is 72,325,926 shares, and hedge funds decreased their holdings by 291.3K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology